CollPlant Biotechnologies (FRA:CPT) Beta: N/A (As of Jul. 06, 2026)


FRA:CPT CollPlant Biotechnologies Ltd FRA:CPT
22 GF Score
Price €0.27
GF Value €0.23
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is CollPlant Biotechnologies Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-06), CollPlant Biotechnologies's Beta is Not available.

CollPlant Biotechnologies  (FRA:CPT) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

CollPlant Biotechnologies Beta Related Terms

CollPlant Biotechnologies Beta Historical Data

* Premium members only.

The historical data trend for CollPlant Biotechnologies's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CollPlant Biotechnologies Beta Chart

CollPlant Biotechnologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CollPlant Biotechnologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:CPT
22GF Score
CollPlant Biotechnologies Ltd FRA:CPT
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CollPlant Biotechnologies Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is CollPlant Biotechnologies (FRA:CPT) Overvalued in 2026?

Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued. The current stock price of €0.27 is trading 15.7% above its estimated GF Value™ of €0.23. GuruFocus considers CollPlant Biotechnologies to be Modestly Overvalued.

Key valuation signals for FRA:CPT:

  • Beta: N/A
  • GF Value™: €0.23 vs. price of €0.27 (15.7% above fair value)
  • GF Score™: 22/100 with 4 warning signs

No single metric tells the full story. See the FRA:CPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CollPlant Biotechnologies Business Description

Other Exchanges CLGN:USA
Address 4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
22GF Score

Get the complete analysis for FRA:CPT

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.27
Price
€0.23
GF Value